There is a high unmet need for new drugs to treat HCV infection. The current gold standard therapy comprises pegylated-alpha interferon (IFN) plus ribavirin (RBV). The efficacy rate of this combination is relatively low (approximately 50%) and both drugs are associated with significant side effects that often lead to treatment discontinuation. Several new antiviral drugs targeting multiple virus and host targets are currently in development. Rapidly emerging drug resistance suggest that combination therapies with multiple classes of drugs will be required to achieve sustained virological response.
The tender offer is subject to customary conditions and is expected to close in December 2008.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit http://www.gsk.com
About the ID CEDD
The ID CEDD is a global research unit within GSK Drug Discovery
dedicated to discovering therapies for infectious diseases. It is designed
to integrate and better coordinate the progression of infectious diseases
medicines from therapeutic hypothesis to clinical proof of concept. While
drawing from the broader resources of GSK's R&D organization, the ID CEDD
bridges the conventional gap between discovery and development, brings
scientists and physicians together in an entrepreneurial environment and
size of small biotechnolo
Copyright©2008 PR Newswire.
All rights reserved